文献速递血栓与止血

血友病B延长半衰期凝血因子IX制品在外部质控评估中的检测性能

Performance of factor IX extended half-life product measurements in external quality control assessment programs.
PubMed 文献 · J Thromb Haemost · 2020-06-10

ECAT、UKNEQAS和RCPAQAP联合开展全球调查,用添加重组FIX及三种EHL FIX制品的FIX缺乏血浆评估检测质量。结果显示不同制品和试剂间FIX活性检测差异大,N9-GP在多数硅基法检测中偏高,需标准化检测。

要点

  • EHL FIX制品检测差异大,需关注试剂选择。
  • N9-GP在多数硅基法检测中活性偏高。
  • 应标准化并提高EHL FIX检测可靠性。

核心结论

  • 重组FIX及EHL FIX制品给药后FIX活性检测存在很大变异。
  • N9-GP在多数硅基法检测中显示尤其高的水平。
  • 必须标准化并提高这些制品的检测可靠性。

研究设计与样本

  • ECAT、UKNEQAS和RCPAQAP联合开展全球调查。
  • 使用添加rFIX、rFIXFP、rFIXFc和N9-GP至6 IU/dL和60 IU/dL的FIX缺乏血浆样本。
  • 参与者使用常规方法,包括一期法(OSA)或发色法(CA)。

主要发现

  • 6 IU/dL样本中,OSA检测中位数(25%-75%范围):rFIX为8.0 IU/dL(7.0-9.2),rFIXFP为6.0 IU/dL(4.0-7.1),rFIXFc为6.6 IU/dL(5.5-8.0),N9-GP为4.9 IU/dL(3.5-8.4)。
  • 60 IU/dL样本中,OSA检测中位数(25%-75%范围):rFIX为63.0 IU/dL(59.9-67.0),rFIXFP为42.5 IU/dL(28.2-47.0),rFIXFc为50.0 IU/dL(45.0-55.0),N9-GP为34.0 IU/dL(24.8-67.5)。
  • 所有样本中不同试剂间观察到 considerable 差异。
  • CA检测也存在相当变异,但试剂间无差异。

临床怎么用

  • 临床监测EHL FIX制品时需了解所用检测方法与试剂的性能差异。
  • 对N9-GP尤其注意硅基法可能高估活性。
  • 推动标准化以保障诊断和治疗监测的可靠性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with hemophilia B are increasingly treated with extended half-life (EHL) factor IX (FIX) concentrates. For the laboratory, introduction of these EHL concentrates presents a major challenge. To understand the variation in FIX activity levels, all available diagnostic assays need to be directly compared. METHODS: The ECAT, UKNEQAS, and RCPAQAP have collaboratively performed a global survey to evaluate the quality of FIX measurements using FIX deficient plasma samples spiked with recombinant FIX (rFIX), rFIXFP, rFIXFc, and N9-GP to levels at typical FIX trough (6 IU/dL) and peak levels (60 IU/dL). Participants were asked to use their routine protocols, using one-stage assays (OSA) or chromogenic assays (CA). RESULTS: In samples spiked with 6 IU/dL product, median (25%-75% range) FIX activity levels (OSA), were 8.0 IU/dL (7.0-9.2) for rFIX, 6.0 IU/dL (4.0-7.1) for rFIXFP, 6.6 IU/dL (5.5-8.0) for rFIXFc, and 4.9 IU/dL (3.5-8.4) for N9-GP. In samples spiked with 60 IU/dL, FIX activity levels measured (using OSA) was 63.0 IU/dL (59.9-67.0) for rFIX, 42.5 IU/dL (28.2-47.0) for rFIXFP, 50.0 IU/dL (45.0-55.0) for rFIXFc, and 34.0 IU/dL (24.8-67.5) for N9-GP. Considerable differences were observed between reagents for all samples. With CA, there was also quite some variation, but no differences between reagents. CONCLUSION: Large variation is observed in the measurement of FIX activity levels after administration of rFIX and EHL FIX products. For N9-GP, most silica-based assays show especially high levels. It is essential to standardize and improve reliability of measurements of these concentrates as diagnosis and treatment monitoring is based on these results.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Nederlof A, Kitchen S, Meijer P, et al. Performance of factor IX extended half-life product measurements in external quality control assessment programs. J Thromb Haemost. 2020. PMID: 32311825. doi:10.1111/jth.14847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。